View : 25 Download: 0

The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 2. Management of H1-Antihistamine-Refractory Chronic Urticaria

Title
The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 2. Management of H1-Antihistamine-Refractory Chronic Urticaria
Authors
Choi, Jeong-HeeLee, Dong HunSong, Woo-JungChoi, MiraKwon, Jae-WooKim, Gun-WooKim, Myung HwaKim, Mi-AeKim, Min-HyeKim, Byung-KeunKim, SujeongKim, Joung SooKim, Jung EunKim, Ju-YoungKim, Joo-HeeKim, Hyun JungKim, Hye OneKim, Hyo-BinRoh, Joo YoungPark, Kyung HeePark, Kui YoungPark, Han-KiPark, HyunsunBae, Jung MinByun, Ji YeonSong, Dae JinAhn, Young MinLee, Seung EunLee, Young BokLee, Joong SunLee, Ji HyunLim, Kyung-HwanYoun, Sang WoongChang, Yoon-SeokJeon, You HoonJeon, JiehyunJue, Mihn-SookChoi, Sun HeeHur, Gyu-YoungLim, Dae HyunYe, Young-MinPark, Young Min
Ewha Authors
변지연김민혜
SCOPUS Author ID
변지연scopus
Issue Date
2020
Journal Title
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
ISSN
2092-7355JCR Link

2092-7363JCR Link
Citation
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH vol. 12, no. 5, pp. 750 - 770
Keywords
Urticariaantihistamine, treatmentguidelineevidenceleukotrieneIgEcyclosporine
Publisher
KOREAN ACAD ASTHMA ALLERGY &

CLINICAL IMMUNOLOGY
Indexed
SCIE; SCOPUS; KCI WOS
Document Type
Review
Abstract
Quite a few patients with chronic spontaneous urticaria (CSU) are refractory to H-1-antihistamines, even though the dose of H-1-antihistamines is increased up to 4-fold. CSU that is not controlled with H-1-antihistamines results in increased disease burden. Several immunomodulators have been used to manage these patients. The guidelines reported herein are connected to Part 1 of the KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children, and aimed to provide evidence-based recommendations for the management of H-1-antihistamine-refractory CSU. Part 2 focuses on the more commonly used additional treatment options for refractory CSU, including omalizumab, cyclosporine, leukotriene receptor antagonist, dapsone, methotrexate, and phototherapy. The evidence to support their efficacy, dosing, safety, and selection of these agents is systematically reviewed. To date, for patients with refractory CSU, the methodologically sound data to evaluate the use of omalizumab has been growing; however, the evidence of other immunomodulators and phototherapy is still insufficient. Therefore, an individualized stepwise approach with a goal of achieving complete symptom control and minimizing side effects can be recommended. Larger controlled studies are needed to elevate the level of evidence to select a rational therapeutic agent for patients with refractory CSU.
DOI
10.4168/aair.2020.12.5.750
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE